• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Flomoxef in neonates and young infants; clinical efficacy, pharmacokinetic evaluation and effect on the intestinal bacterial flora].

作者信息

Fujita K, Murono K, Saijyo M, Kakuya F, Yoshioka H, Maruyama S, Sakata H, Hiramoto A, Inyaku F

机构信息

Department of Pediatrics, Asahikawa Medical College.

出版信息

Jpn J Antibiot. 1991 Nov;44(11):1216-27.

PMID:1784072
Abstract

Forty-three newborn and young infants including 13 low-birth-weight (LBW) infants were treated with flomoxef (FMOX) and the clinical efficacy and side effect were evaluated. The ages of the patients ranged from 0 to 99 days, and their body weights from 797 to 9,000 g. Dose levels were 10.5 to 48.5 mg/kg every 6 to 8 hours for 3 to 12 days. Those patients who responded to the FMOX treatment included 8 infants with sepsis, 14 with suspected sepsis, 6 with intrauterine infection, 2 with meningitis, 7 with pneumonia, 1 with staphylococcal scalded skin syndrome, 1 with epididymitis and 4 with urinary tract infections. The results were excellent in 17 and good in 22 patients. The drug was well tolerated, although diarrhea occurred in 2, slightly elevated serum concentrations of transaminases in 2, and eosinophilia and thrombocytosis in 1 patient each. Pharmacokinetic studies on FMOX with 20 mg/kg dose were done in 19 patients including 8 LBW infants. Serum concentrations at 15 minutes after intravenous bolus injection in five 1- to 6-day-old LBW, five 1- to 6-day-old and four 8- to 19-day-old mature infants were 52.6, 52.7 and 58.0 micrograms/ml, respectively, and those at 4 hours were 22.1, 13.3 and 5.2 micrograms/ml, respectively. Serum half-lives of the drug were 3.93, 2.29 and 1.62 hours, respectively, and excretion rates of this drug into urine in the first 6 hours after administration were 30.4, 45.1 and 58.7%, respectively. Mean serum concentrations just after intravenous 1-hour drip infusion in three 8- to 54-day-old LBW and two 8- and 10-day-old mature infants, were 31.5 and 18.9 micrograms/ml, respectively, and those at 4 hours were 15.3 and 4.3 micrograms/ml, respectively. Serum half-lives of the drug were 2.88 and 1.75 hours, respectively, and excretion rates of the drug into urine in the first 6 hours were 22.6 and 47.5%, respectively. The cerebrospinal fluid level at 3 hours after a dose was 7.09 micrograms/ml on the second day of treatment in a patient with Staphylococcus aureus meningitis receiving 50 mg/kg of the drug every 6 hours per day. Its level at 1 hour after a dose was 3.52 micrograms/ml on the 8th day of treatment in the same patient. The influence of FMOX on the fecal flora was studied in 7 patients. The characteristic pattern observed during the drug administration was the disappearance of Bifidobacterium, the decrease or disappearance of Enterobacteriaceae and the preservation of Streptococcus.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
[Flomoxef in neonates and young infants; clinical efficacy, pharmacokinetic evaluation and effect on the intestinal bacterial flora].
Jpn J Antibiot. 1991 Nov;44(11):1216-27.
2
[Ceftriaxone in neonates and young infants; clinical efficacy, pharmacokinetic evaluation and effect on intestinal bacterial flora].
Jpn J Antibiot. 1988 Feb;41(2):117-27.
3
[Laboratory and clinical evaluations of flomoxef sodium in neonates].
Jpn J Antibiot. 1991 Nov;44(11):1265-85.
4
[Pharmacokinetic and clinical studies on flomoxef in neonates and premature infants].氟氧头孢在新生儿及早产儿中的药代动力学与临床研究
Jpn J Antibiot. 1991 Nov;44(11):1240-9.
5
[Pharmacokinetics and clinical efficacy of flomoxef in neonates].氟氧头孢在新生儿中的药代动力学及临床疗效
Jpn J Antibiot. 1991 Nov;44(11):1228-39.
6
[Pharmacokinetics and clinical studies of flomoxef in the pediatric field].
Jpn J Antibiot. 1987 Aug;40(8):1515-34.
7
[Pharmacokinetic and clinical studies of ceftizoxime in newborn infants].
Jpn J Antibiot. 1988 Aug;41(8):1053-64.
8
[Fundamental and clinical evaluation of cefozopran in low birth weight infants and neonates].头孢唑肟在低体重婴儿和新生儿中的基础与临床评估
Jpn J Antibiot. 1997 Dec;50(12):917-35.
9
[Laboratory and clinical studies of flomoxef in the pediatric field].
Jpn J Antibiot. 1987 Aug;40(8):1426-38.
10
[Pharmacokinetics and clinical studies on flomoxef in neonates and premature infants. A study of flomoxef in the perinatal collaboration research group].氟氧头孢在新生儿和早产儿中的药代动力学及临床研究。围产期协作研究组关于氟氧头孢的一项研究
Jpn J Antibiot. 1993 Jul;46(7):518-38.

引用本文的文献

1
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.氟莫头孢治疗新生儿:为产 ESBL 肠杆菌科导致的新生儿败血症治疗提供更多选择。
J Antimicrob Chemother. 2022 Feb 23;77(3):711-718. doi: 10.1093/jac/dkab468.
2
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.用于治疗多重耐药菌引起的新生儿败血症的潜在抗生素
Paediatr Drugs. 2021 Sep;23(5):465-484. doi: 10.1007/s40272-021-00465-z. Epub 2021 Aug 26.